Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

SAB2501521

Sigma-Aldrich

Anti-PCSK9 antibody produced in goat

affinity isolated antibody, buffered aqueous solution

Sinónimos:

Anti-FH3, Anti-HCHOLA3, Anti-LDLCQ1, Proprotein convertase subtilisin/kexin type 9

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

origen biológico

goat

Nivel de calidad

conjugado

unconjugated

forma del anticuerpo

affinity isolated antibody

tipo de anticuerpo

primary antibodies

clon

polyclonal

Formulario

buffered aqueous solution

reactividad de especies

mouse, human, rat

técnicas

indirect ELISA: suitable
western blot: suitable

Nº de acceso UniProt

Condiciones de envío

dry ice

temp. de almacenamiento

−20°C

modificación del objetivo postraduccional

unmodified

Información sobre el gen

human ... PCSK9(255738)

Descripción general

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) codes for a secretory serine protease predominantly expressed in liver and intestine. The PCSK9 gene is mapped to human chromosome 1p32.3 and is highly polymorphic.. PCSK9 is also expressed in vascular smooth muscle cells.

Inmunógeno

Peptide with sequence TRFHRQASKCDSHGT, from the internal region of the protein sequence according to NP_777596.2

Acciones bioquímicas o fisiológicas

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) promotes lysosomal degradation of LDLR (low density lipoprotein receptor), VLDL (very low density lipoprotein receptor) and LRP (LDL related protein) to cause clearance of plasma cholesterol. On the other hand, PCSK9 also stimulates the release of chylomicron in intestinal cells. Lower intracellular cholesterol and mutations such as gain of function stimulates the expression of PCSK9. Autosomal dominant hypercholesterolemia is a result of high LDLR-degradation caused due to mutated PCSK9. PCSK9 is known to prevent the entry and replication of hepatitis C virus. PCSK9 expression is observed in atherosclerotic plaques.

Características y beneficios

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Forma física

Supplied at 0.5 mg/mL in 20mM Tris (pH 7.3) and 150mM NaCl with 0.02% sodium azide and 0.5% bovine serum albumin.

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Ruscica M, et al.
Journal of the American Heart Association, 6(5), e005764-e005764 (2017)
The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
Drouin-Chartier J P, et al.
Lipids in Health and Disease, 16(1), 119-119 (2017)
Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.
Arama C, et al.
PLoS ONE, 13(2), e0192850-e0192850 (2018)
Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity.
Li Z and Liu Q
Biochemical and Biophysical Research Communications, 496(4), 1229-1235 (2018)
What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis.
Qiu C, et al.
Lipids in Health and Disease, 16(1), 111-111 (2017)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico